Cadrenal Therapeutics presented late-breaking Phase 2 data for 12-lipoxygenase inhibitor CAD-1005 showing >25% reduction in thrombotic events in Heparin-Induced Thrombocytopenia. This supports the drug’s potential efficacy signal from the ongoing study, which may be modestly supportive for investor sentiment in the near term.
Cadrenal Therapeutics presented late-breaking Phase 2 data for 12-lipoxygenase inhibitor CAD-1005 showing >25% reduction in thrombotic events in Heparin-Induced Thrombocytopenia. This supports the drug’s potential efficacy signal from the ongoing study, which may be modestly supportive for investor sentiment in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
